37 related articles for article (PubMed ID: 23797006)
1. Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders.
Locatelli F; Del Vecchio L
Expert Rev Cardiovasc Ther; 2015 May; 13(5):489-99. PubMed ID: 25804298
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J; Covic AC; Ketteler M; Mann JF; Rastogi A; Spinowitz B; Chong EM; Gaillard S; Lisk LJ; Sprague SM;
Nephrol Dial Transplant; 2015 Jun; 30(6):1037-46. PubMed ID: 25691681
[TBL] [Abstract][Full Text] [Related]
3. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
[TBL] [Abstract][Full Text] [Related]
4. Systemic network for dietary inorganic phosphate adaptation among three organs.
Ikuta K; Segawa H; Hanazaki A; Fujii T; Kaneko I; Shiozaki Y; Tatsumi S; Ishikawa Y; Miyamoto KI
Pflugers Arch; 2019 Jan; 471(1):123-136. PubMed ID: 30523405
[TBL] [Abstract][Full Text] [Related]
5. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
6. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
Cernaro V; Santoro D; Lacquaniti A; Costantino G; Visconti L; Buemi A; Buemi M
Int J Nephrol Renovasc Dis; 2016; 9():11-9. PubMed ID: 26893577
[TBL] [Abstract][Full Text] [Related]
8. Phosphate binders in chronic kidney disease: a systematic review of recent data.
Floege J
J Nephrol; 2016 Jun; 29(3):329-340. PubMed ID: 26800972
[TBL] [Abstract][Full Text] [Related]
9. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
[TBL] [Abstract][Full Text] [Related]
10. What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?
Oh MS; Uribarri J
Clin J Am Soc Nephrol; 2014 May; 9(5):967-70. PubMed ID: 24408115
[TBL] [Abstract][Full Text] [Related]
11. Effect of salivary phosphate-binding chewing gum on serum phosphate in chronic kidney disease.
Block GA; Persky MS; Shamblin BM; Baltazar MF; Singh B; Sharma A; Pergola P; Smits G; Comelli MC
Nephron Clin Pract; 2013; 123(1-2):93-101. PubMed ID: 23797006
[TBL] [Abstract][Full Text] [Related]
12. Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: a multi-center, randomized, double-blind, placebo-controlled trial.
Akizawa T; Tsuruta Y; Okada Y; Miyauchi Y; Suda A; Kasahara H; Sasaki N; Maeda Y; Suzuki T; Matsui N; Niwayama J; Suzuki T; Hara H; Asano Y; Komemushi S; Fukagawa M
BMC Nephrol; 2014 Jun; 15():98. PubMed ID: 24968790
[TBL] [Abstract][Full Text] [Related]
13. Salivary glands: a new player in phosphorus metabolism.
Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
[TBL] [Abstract][Full Text] [Related]
14. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.
Savica V; Calò LA; Monardo P; Davis PA; Granata A; Santoro D; Savica R; Musolino R; Comelli MC; Bellinghieri G
J Am Soc Nephrol; 2009 Mar; 20(3):639-44. PubMed ID: 19020004
[TBL] [Abstract][Full Text] [Related]
15. [Salivary phosphate-binding chewing gum--an integrative approach to chronic kidney disease and oral diseases].
Wilczyńska-Borawska M; Borawski J; Stokowska W
Przegl Lek; 2011; 68(9):633-6. PubMed ID: 22335015
[TBL] [Abstract][Full Text] [Related]
16. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder.
Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA
Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
